On 12/20/18, Relay Therapeutics announced the successful completion of a $400 million Series C financing.
Relay Therapeutics combines unprecedented computational power with leading... read more
On 12/20/18, Relay Therapeutics announced the successful completion of a $400 million Series C financing.
Relay Therapeutics combines unprecedented computational power with leading... read more
Equillium, Inc. (Nasdaq: EQ) announced on 12/19/18 that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EQ001 for the treatment of acute graft-versus-host... read more
Auron Therapeutics and Elucidata Corporation on 12/19/18 announced a scientific collaboration using Elucidata’s AI-based target discovery platform to identify and validate targets for... read more
Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, announced on 12/19/18 that... read more
